tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2026-104-2-98-109tiblj-1965Research ArticleОБЗОРREVIEWСпособы доставки линезолида к очагу туберкулезного воспаления: систематический обзорLinezolid Delivery Methods to the Site of Tuberculosis Inflammation: a Systematic Reviewhttps://orcid.org/0000-0002-4132-0049РомановаМ. И.RomanovM. I.

Романова Мария Игоревна - Младший научный сотрудник отдела  дифференциальной диагностики  и лечения туберкулеза и сочетанных инфекций  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Maria I. Romanova - Junior Researcher of Department  of Differential Diagnosis and Treatment  of Tuberculosis and Concurrent Infections 

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

romanovaMI@nmrc.ruhttps://orcid.org/0000-0002-3138-6538ГайдаА. И.GaydaA. I.

Гайда Анастасия Игоревна - 

К. м. н., старший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Anastasiya I. Gayda - Candidate of Medical Sciences,  Senior Researcher of Department  of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections  

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

nsovca@yandex.ruhttps://orcid.org/0000-0002-2292-1228ТюльковаТ. Е.TyulkovaT. E.

Тюлькова Татьяна Евгеньевна - Д. м. н., ведущий специалист отдела социально –  значимых инфекций  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Tatyana E. Tyulkova - Doctor of Medical Sciences,Leading Specialist of Socially Important Infections Department  

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

TiulkovaTE@nmrc.ruhttps://orcid.org/0009-0009-3794-9627СергееваВ. И.SergeevaV. I.

Сергеева Валерия Ильинична - Младший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Valeriya I. Sergeeva - Junior Researcher of Department  of Differential Diagnosis and Treatment  of Tuberculosis and Concurrent Infections

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

leris7snoopy@mail.ruhttps://orcid.org/0000-0002-6366-4491Ле-ДейгенИ. М.Le-DeygenI. M.

Ле-Дейген Ирина Михайловна, К. м. н., доцент кафедры химической энзимологии химического факультета 

119991, Москва, ул. Ленинские горы, д. 1

Тел.: +7 (495) 939-10-00

Irina M. Le-Deygen - Candidate of Medical Sciences, Associate Professor  of Chemical Enzymology Department,  Faculty of Chemistry

1 Leninskie Gory St., Moscow, 119991

Phone: +7 (495) 939-10-00

i.m.deygen@gmail.comhttps://orcid.org/0000-0002-1177-2968КолмогоровИ. М.KolmogorovI. M.

Колмогоров Илья Михайлович - Младший научный сотрудник кафедры химической энзимологии химического факультета  

119991, Москва, ул. Ленинские горы, д. 1

Тел.: +7 (495) 939-10-00

Ilya M. Kolmogorov - Junior Researcher of Chemical Enzymology Department, Faculty of Chemistry 

1 Leninskie Gory St., Moscow, 119991

Phone: +7 (495) 939-10-00

kolmogorov2001@mail.ruhttps://orcid.org/0000-0002-4769-5933АвдеевВ. В.AvdeevV. V.

Авдеев Вадим Вадимович - Научный сотрудник научной лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Vadim V. Avdeev - Researcher of Research Laboratory of Immunopathology  and Immunodiagnostics of Tuberculosis Infection 

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

 

avdeevvv@nmrc.ruhttps://orcid.org/0000-0002-5396-7552МожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна, Д. м. н., ведущий научный сотрудник научной лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

 

Galina N. Mozhokina - Doctor of Medical Sciences, Leading Researcher  of Research Laboratory of Immunopathology  and Immunodiagnostics of Tuberculosis Infection  

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

mojokina@mail.ruhttps://orcid.org/0000-0001-6596-9777СамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна - Д. м. н., заместитель директора по научной работе  

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.: +7 (495) 631-15-15

Anastasiya G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research

Build. 2, 4 Dostoevskiy St., Moscow, 127473

Phone: +7 (495) 631-15-15

a.samoilova.nmrc@mail.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian FederationФГБОУ ВПО «Московский государственный университет имени М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian Federation202614052026104298109Copyright © Романова М.И., Гайда А.И., Тюлькова Т.Е., Сергеева В.И., Ле-Дейген И.М., Колмогоров И.М., Авдеев В.В., Можокина Г.Н., Самойлова А.Г., 20262026Романова М.И., Гайда А.И., Тюлькова Т.Е., Сергеева В.И., Ле-Дейген И.М., Колмогоров И.М., Авдеев В.В., Можокина Г.Н., Самойлова А.Г.Romanov M.I., Gayda A.I., Tyulkova T.E., Sergeeva V.I., Le-Deygen I.M., Kolmogorov I.M., Avdeev V.V., Mozhokina G.N., Samoylova A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1965

Проанализированы 50 научных источников за период с 2018 по 2025 гг. о способах доставки лекарственных препаратов, а также преимуществах наночастиц линезолида. Противотуберкулезные препараты, принимаемые перорально, не всегда создают достаточную бактерицидную концентрацию в очаге поражения, независимо от их уровня в сыворотке крови. Вследствие этого даже при соблюдении режима лечения примерно у 1% пациентов может развиться туберкулез с множественной лекарственной устойчивостью (МЛУ-ТБ) из-за фармакокинетической вариабельности. Это определяет необходимость создания систем доставки, обеспечивающих таргетную подачу препарата непосредственно в пораженную легочную ткань. Для линезолида разработаны наноформы (сухие порошки, аэрозоли). Они стабильны до 6 месяцев и повышают биодоступность до 55,2%, что позволяет снизить дозу. Это открывает реальные перспективы для снижения терапевтических доз препарата.

50 scientific publications between 2018 and 2025 were analyzed, focusing on drug delivery systems and benefits of linezolid-loaded nanoparticles. Orally administered anti-tuberculosis drugs do not always achieve sufficient bactericidal concentrations at the site of infection, regardless of their serum levels. Consequently, even with treatment adherence, approximately 1% of patients may develop multidrug-resistant tuberculosis (MDR-TB) due to pharmacokinetic variability. This highlights the need for advanced delivery systems that ensure targeted drug release directly into the affected lung tissue. Nanoformulations of linezolid (e.g., dry powders, aerosols) have been developed. These formulations remain stable for up to 6 months and increase bioavailability to 55.2%, enabling dose reduction.  This opens up real prospects for lowering the therapeutic dose of the drug.

система доставки лекарствлинезолиднаночастицылипосомыdrug delivery systemlinezolidnanoparticlesliposomesReferencesAkinnawo C.A, Dube А. Clinically Relevant Metallic Nanoparticles in Tuberculosis Diagnosis and Therapy // Advanced Therapeutics. – 2024. – Vol. 8, № 4. – Р. 2400189.Akinnawo C.A, Dube А. Clinically relevant metallic nanoparticles in tuberculosis diagnosis and therapy. Advanced Therapeutics, 2024, vol. 8, no. 4, pp. 2400189.An H., Deng X., Wang F., Xu P., Wang N. Dendrimers as Nanocarriers for the Delivery of Drugs Obtained from Natural Products // Polymers. – 2023. – Vol. 15, № 10. – Р. 2292. https://doi.org/10.3390/polym15102292An H., Deng X., Wang F., Xu P., Wang N. Dendrimers as nanocarriers for the deliver y of drugs obtained from natural products. Polymers, 2023, vol. 15, no. 10, pp. 2292. https://doi.org/10.3390/polym15102292Bharti Sharma J., Bhatt S., Tiwari A., Tiwari V., Kumar M., Verma R., Kaushik D., Virmani T., Kumar G., Al Kamaly O., Saleh A., Khalid Parvez M., Alhalmi A. Statistical optimization of tetrahydrocurcumin loaded solid lipid nanoparticles using Box Behnken design in the management of streptozotocin-induced diabetes mellitus // Saudi pharmaceutical journal. – 2023. – Vol. 31, № 9. – Р. 101727. https://doi.org/10.1016/j.jsps.2023.101727Bharti Sharma J., Bhatt S., Tiwari A., Tiwari V., Kumar M., Verma R., Kaushik D., Virmani T., Kumar G., Al Kamaly O., Saleh A., Khalid Parvez M., Alhalmi A. Statistical optimization of tetrahydrocurcumin loaded solid lipid nanoparticles using Box Behnken design in the management of streptozotocin-induced diabetes mellitus. Saudi Pharmaceutical Journal, 2023, vol. 31, no. 9, pp. 101727. https://doi.org/10.1016/j.jsps.2023.101727Borkar G., Chemate S. Formulation Development and Evaluation Studies of Linezolid Inhaler in the Treatment of Tuberculosis // International Journal of Pharmaceutical Sciences and Drug Research. – 2023. – Vol. 15, № 6. – Р. 722-729. https://doi.org/10.25004/IJPSDR.2023.150605Borkar G., Chemate S. Formulation development and evaluation studies of linezolid inhaler in the treatment of tuberculosis. International Journal of Pharmaceutical Sciences and Drug Research, 2023, vol. 15, no. 6, pp. 722-729. https://doi.org/10.25004/IJPSDR.2023.150605Burmistrova I.A. Vaniev E.V., Samoylova A.G., et al. The effectiveness of various approaches to the treatment of patients with isoniazid-resistant pulmonary tuberculosis // Tuberculosis and lung diseases. – 2023. – Vol. 101, № 5. – Р. 26-30.Burmistrova I.A., Vaniev E.V., Samoylova A.G. et al. The effectiveness of various approaches to the treatment of patients with isoniazid-resistant pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 5, pp. 26-30.Buya A.B., Witika B.A., Bapolisi A.M., Mwila C., Mukubwa G.K., Memvanga P.B., Makoni P.A., Nkanga C.I. Application of lipid-based nanocarriers for antitubercular drug delivery: a review // Pharmaceutics. – 2021. – Vol. 13, № 12. – Р. 2041. https://doi.org/10.3390/pharmaceutics13122041Buya A.B., Witika B.A., Bapolisi A.M., Mwila C., Mukubwa G.K., Memvanga P.B., Makoni P.A., Nkanga C.I. Application of lipid-based nanocarriers for antitubercular drug delivery: a review. Pharmaceutics, 2021, vol. 13, no. 12, pp. 2041. https://doi.org/10.3390/pharmaceutics13122041Chikaura H., Nakashima Y., Fujiwara Y., Komohara Y., Takeya M., Nakanishi Y. Effect of particle size on biological response by human monocyte-derived macrophages // Biosurf Biotribol. – 2016. – Vol. 2, № 1. – Р. 18-25. https://doi.org/10.1016/j.bsbt.2016.02.003Chikaura H., Nakashima Y., Fujiwara Y., Komohara Y., Takeya M., Nakanishi Y. Effect of particle size on biological response by human monocyte-derived macrophages. Biosurf. Biotribol., 2016, vol. 2, no. 1, pp. 18-25. https://doi.org/10.1016/j.bsbt.2016.02.003Cirillo D.M., Miotto P., Tagliani E., ReSeqTB Consortium. Reaching consensus on drug resistance conferring mutations // International journal of mycobacteriology. – 2016. – Vol. 5, № 1. – Р. 33. https://doi.org/10.1016/j.ijmyco.2016.11.009Cirillo D.M., Miotto P., Tagliani E., ReSeqTB Consortium. Reaching consensus on drug resistance conferring mutations. International Journal of Mycobacteriology, 2016, vol. 5, no. 1, pp. 33. https://doi.org/10.1016/j.ijmyco.2016.11.009Colone M., Calcabrini A., Stringaro A. Drug Delivery Systems of Natural Products in Oncology // Molecules. – 2020. – Vol. 25, № 19. – Р. 4560. https://doi.org/10.3390/molecules25194560Colone M., Calcabrini A., Stringaro A. Drug delivery systems of natural products in oncology. Molecules, 2020, vol. 25, no. 19, pp. 4560. https://doi.org/10.3390/molecules25194560Dallal Bashi Y.H., Mairs R., Murtadha R., Kett V. Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects // Pharmaceutics. – 2025. – Vol. 17, № 1. – Р. 111.Dallal Bashi Y.H., Mairs R., Murtadha R., Kett V. Pulmonary delivery of antibiotics to the lungs: current state and future prospects. Pharmaceutics, 2025, vol. 17, no. 1, pp. 111.Dua K., Hansbro P.M., Wadhwa R., Haghi M., Pont L.G., Williams K.A. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Academic Press, 2020. Available at: https://shop.elsevier.com/books/targeting-chronic-inflammatory-lung-diseases-using-advanced-drug-delivery-systems/dua/978-0-12-820658-4 [Accessed 27.09.2025].Dua K., Hansbro P.M., Wadhwa R., Haghi M., Pont L.G., Williams K.A. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Academic Press Publ., 2020. Available: https://shop.elsevier.com/books/targeting-chronic-inflammatorylung-diseases-using-advanced-drug-delivery-systems/dua/978-0-12-820658-4 Accessed September 27, 2025French G. Safety and tolerability of linezolid // The Journal of antimicrobial chemotherapy. – 2003. – Vol. 51, Suppl 2. – Р. ii45-ii53. https://doi.org/10.1093/jac/dkg253French G. Safety and tolerability of linezolid. The Journal of Antimicrobial Chemotherapy, 2003, vol. 51, suppl. 2, pp. ii45-ii53. https://doi.org/10.1093/jac/dkg253Garrabou G., Soriano A., López S., Guallar J.P., Giralt M., Villarroya F., Martínez J.A., Casademont J., Cardellach F., Mensa J., Miró Ò. Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia // Antimicrob Agents Chemother. – 2007. – Vol. 51, № 3. – Р. 962-967. https://doi.org/10.1128/aac.01190-06Garrabou G., Soriano A., López S., Guallar J.P., Giralt M., Villarroya F., Martínez J.A., Casademont J., Cardellach F., Mensa J., Miró Ò. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother., 2007, vol. 51, no. 3, pp. 962-967. https://doi.org/10.1128/aac.01190-06Geiser M. Morphological aspects of particle uptake by lung phagocytes // Microscopy research and technique. – 2002. – Vol. 57, № 6. – Р. 512-522. https://doi.org/10.1002/jemt.10105Geiser M. Morphological aspects of particle uptake by lung phagocytes. Microscopy Research and Technique, 2002, vol. 57, no. 6, pp. 512-522. https://doi.org/10.1002/jemt.10105Global Tuberculosis Report 2024 / World Health Organization. – Geneva, 2024. – 68 pGlobal Tuberculosis Report 2024. World Health Organization, Geneva, 2024, 68 pGomez A.I., Acosta M.F., Muralidharan P., et al. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery // Pulmonary pharmacology & therapeutics. – 2020. – № 64. – Р. 101975. https://doi.org/10.1016/j.pupt.2020.101975Gomez A.I., Acosta M.F., Muralidharan P. et al. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery. Pulmonary Pharmacology & Therapeutics, 2020, no. 64, pp. 101975. https://doi.org/10.1016/j.pupt.2020.101975Goswami R. The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage // Oman Medical Journal. – 2020 – Vol. 35, № 6. – Р. 194. https://doi.org/10.5001/OMJ.2020.78Goswami R. The role of metallic nanoparticles in inhibition of Mycobacterium tuberculosis and enhances phagosome maturation into the infected macrophage. Oman Medical Journal, 2020, vol. 35, no. 6, pp. 194. https://doi.org/10.5001/OMJ.2020.78Imperial M.Z., Nedelman J.R., Conradie F., Savic R.M. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis // Clinical infectious diseases. – 2022. – Vol. 74, № 10. – Р. 1736-1747. https://doi.org/10.1093/cid/ciab699Imperial M.Z., Nedelman J.R., Conradie F., Savic R.M. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clinical Infection Diseases, 2022, vol. 74, no. 10, pp. 1736-1747. https://doi.org/10.1093/cid/ciab699Isles M.P. Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety // Frontiers in pharmacology. – 2022. – № 12. – Р. 787239. https://doi.org/10.3389/fphar.2021.787239Isles M.P. Nanomedicines and nanosimilars-why a robust centralised regulatory framework is essential to enhance patient safety. Frontiers in Pharmacology, 2022, no. 12, pp. 787239. https://doi.org/10.3389/fphar.2021.787239Kamble R.N. Development and Characterization of Linezolid loaded Biocompatible Solid-lipid based Nanocarrier for Enhanced Lung Deposition and Anti-tubercular Activity tailor-made Carrier for Dry Powder Inhaler //Current Indian Science. – 2023. – Vol. 1. – №. 1. – Р. E080523216630.Kamble R.N. Development and characterization of linezolid loaded biocompatible solid-lipid based nanocarrier for enhanced lung deposition and anti-tubercular activity tailor-made carrier for dry powder inhaler. Current Indian Science, 2023, vol. 1, no. 1, pp. E080523216630.Kempker R.R., Heinrichs M.T., Nikolaishvili K., Sabulua I., Bablishvili N., Gogishvili S., Avaliani Z., Little B.P., Bernheim A., Derendorf H., Blumberg H.M., Vashakidze S., Peloquin C.A. A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis // The European respiratory journal. – 2018. – Vol. 51, № 2. – Р. 1702166.Kempker R.R., Heinrichs M.T., Nikolaishvili K., Sabulua I., Bablishvili N., Gogishvili S., Avaliani Z., Little B.P., Bernheim A., Derendorf H., Blumberg H.M., Vashakidze S., Peloquin C.A. A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. The European Respiratory Journal, 2018, vol. 51, no. 2, pp. 1702166.Kesharwani P. (ed.) Nanotechnology based approaches for tuberculosis treatment. – Academic Press, 2020. Available at: https://shop.elsevier.com/books/nanotechnology-based-approachesfor-tuberculosis-treatment/kesharwani/978-0-12-819811-7 [Accessed 27.09.2025].Kesharwani P. (ed.) Nanotechnology based approaches for tuberculosis treatment. Academic Press Publ., 2020. Available: https://shop.elsevier.com/books/nanotechnology-based-approachesfor-tuberculosis-treatment/kesharwani/978-0-12-819811-7 Accessed September 27, 2025Kumar G., Virmani T., Pathak K., Kamaly O.A., Saleh A. Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation // Pharmaceuticals (Basel). – 2022. – Vol. 15. № 11. – Р. 1343. https://doi.org/10.3390/ph15111343Kumar G., Virmani T., Pathak K., Kamaly O.A., Saleh A. Central composite design implemented azilsartan medoxomil loaded nanoemulsion to improve its aqueous solubility and intestinal permeability: in vitro and ex vivo evaluation. Pharmaceuticals (Basel), 2022, vol. 15, no. 11, pp. 1343. https://doi.org/10.3390/ph15111343Kumar G., Virmani T., Sharma A., Pathak K. Codelivery of phytochemicals with conventional anticancer drugs in form of nanocarriers // Pharmaceutics. – 2023. – Vol. 15, № 3. – Р. 889. https://doi.org/10.3390/pharmaceutics15030889Kumar G., Virmani T., Sharma A., Pathak K. Codelivery of phytochemicals with conventional anticancer drugs in form of nanocarriers. Pharmaceutics, 2023, vol. 15, no. 3, pp. 889. https://doi.org/10.3390/pharmaceutics15030889Makled S., Boraie N., Nafee N. Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis // Drug Deliv Transl Res. – 2021. – Vol. 11, № 3. – Р.1037-1055. https://doi.org/10.1007/s13346-020-00815-3Makled S., Boraie N., Nafee N. Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis. Drug Deliv. Transl. Res., 2021, vol. 11, no. 3, pp. 1037-1055. https://doi.org/10.1007/s13346-020-00815-3Mater J., Chem B. Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis // Journal of Materials Chemistry B. – 2019. – № 7. – Р. 4338-4346. https://doi.org/10.1039/C9TB00784AMater J., Chem B. Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis. Journal of Biological Chemistry, 2019, no. 7, pp. 4338-4346. https://doi.org/10.1039/C9TB00784AMeravanige G., Thippeswamy M., Shiroorkar P., et al. Chitosan-Based Linezolid Dry Powder Inhalers: A Novel Approach for Targeted Pulmonary Delivery in Tuberculosis Treatment // Indian Journal of Pharmaceutical Education and Research. – 2025. – Vol. 59. – № 1s. – P. s138-s150.Meravanige G., Thippeswamy M., Shiroorkar P. et al. Chitosan-based linezolid dry powder inhalers: a novel approach for targeted pulmonary delivery in tuberculosis treatment. Indian Journal of Pharmaceutical Education and Research, 2025, vol. 59, no. 1s, pp. s138-s150.Muravyeva A.I., Zavarzina V.V., Gukasova N.V., Kuznetsov S.L., Tubasheva I.A., Vorontsov E.A. Complex polymer compositions based on antibiotics linezolid, rifabutin, prothionamide // Issues of biological, medical and pharmaceutical chemistry. – 2018 – Vol. 21, № 5. – Р. 27-33.Muravyeva A.I., Zavarzina V.V., Gukasova N.V., Kuznetsov S.L., Tubasheva I.A., Vorontsov E.A. Complex polymer compositions based on antibiotics linezolid, rifabutin, prothionamide. Issues of Biological, Medical and Pharmaceutical Chemistry, 2018, vol. 21, no. 5, pp. 27-33.Nabi B., Rehman S., Aggarwal S., Baboota S., Ali J. Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention // Drug delivery and translational research. – 2020. – Vol. 10, № 4. – Р. 1111-1121. https://doi.org/10.1007/s13346-020-00786-5Nabi B., Rehman S., Aggarwal S., Baboota S., Ali J. Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention. Drug Delivery and Translational Research, 2020, vol. 10, no. 4, pp. 1111-1121. https://doi.org/10.1007/s13346-020-00786-5Park H., Otte A., Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond // Journal of controlled release: official journal of the Controlled Release Society. – 2022. – № 342. – Р. 53-65. https://doi.org/10.1016/j.jconrel.2021.12.030Park H., Otte A., Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release: Official Journal of the Controlled Release Society, 2022, no. 342, pp. 53-65. https://doi.org/10.1016/j.jconrel.2021.12.030Pham D.D., Fattal E., Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment // International journal of pharmaceutics. – 2015. – Vol. 478, № 2. – Р. 517-529. https://doi.org/10.1016/j.ijpharm.2014.12.009Pham D.D., Fattal E., Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. International Journal of Pharmaceutics, 2015, vol. 478, no. 2, pp. 517-529. https://doi.org/10.1016/j.ijpharm.2014.12.009Rani S., Sharma A.K., Kasu R., Gupta U. Polymeric Nanoparticles: A Holistic Approach to Combat Tuberculosis // Critical reviews in therapeutic drug carrier systems. – 2022. – Vol. 39, № 5. – Р. 83-115. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022039981Rani S., Sharma A.K., Kasu R., Gupta U. Polymeric nanoparticles: a holistic approach to combat tuberculosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2022, vol. 39, no. 5, pp. 83-115. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022039981Shah S., Maheshwari H., Soniwala M., et al. Pulmonary delivery 44of linezolid nanoparticles for treatment of tuberculosis: design, development, and optimization //Journal of Pharmaceutical Innovation. – 2022. – Vol. 17. – № 1. – Р. 46-59.Shah S., Maheshwari H. Soniwala M. et al. Pulmonary delivery of linezolid nanoparticles for treatment of tuberculosis: design, development, and optimization. Journal of Pharmaceutical Innovation, 2022, vol. 17, no. 1, pp. 46-59.Shah S., Cristopher D., Sharma S., et al. Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: design, development and in vitro evaluation //Journal of Drug Delivery Science and Technology. – 2020. – № 60. – P. 102013.Shah S., Cristopher D., Sharma S. et al. Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: design, development and in vitro evaluation. Journal of Drug Delivery Science and Technology, 2020, no. 60, pp. 102013.Sharma Y., Mahar R., Chakraborty A., Nainwal N. Optimizing the formulation variables for encapsulation of linezolid into polycaprolactone inhalable microspheres using double emulsion solvent evaporation //Tuberculosis. – 2023. – № 143. – Р. 102417.Sharma Y., Mahar R., Chakraborty A., Nainwal N. Optimizing the formulation variables for encapsulation of linezolid into polycaprolactone inhalable microspheres using double emulsion solvent evaporation. Tuberculosis, 2023, no. 143, pp. 102417.Sheikhpour M., Delorme V., Kasaeian A., Amiri V., Masoumi M., Sadeghinia M., Ebrahimzadeh N., Maleki M., Pourazar S. An effective nano drug delivery and combination therapy for the treatment of Tuberculosis // Scientific reports. – 2022. – Vol. 12, № 1. – Р. 9591. https://doi.org/10.1038/s41598-022-13682-4Sheikhpour M., Delorme V., Kasaeian A., Amiri V., Masoumi M., Sadeghinia M., Ebrahimzadeh N., Maleki M., Pourazar S. An effective nano drug delivery and combination therapy for the treatment of tuberculosis. Scientific Reports, 2022, vol. 12, no. 1, pp. 9591. https://doi.org/10.1038/s41598-022-13682-4Singh S., Virmani T., Kohli K. Nanoemulsion system for improvement of raspberry ketone oral bioavailability // Indo Global Journal of Pharmaceutical Sciences. – 2020. – Vol. 10, № 01. – Р. 33-42. https://doi.org/10.35652/IGJPS.2020.10105Singh S., Virmani T., Kohli K. Nanoemulsion system for improvement of raspberry ketone oral bioavailability. Indo Global Journal of Pharmaceutical Sciences, 2020, vol. 10, no. 01, pp. 33-42. https://doi.org/10.35652/IGJPS.2020.10105Srivastava S., Pasipanodya J.G., Meek C., Leff R., Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability // The Journal of infectious diseases. – 2011. – Vol. 204, 12. – Р. 1951-1959. https://doi.org/10.1093/infdis/jir658Srivastava S., Pasipanodya J.G., Meek C., Leff R., Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. The Journal of Infectious Diseases, 2011, vol. 204, 12, pp. 1951-1959. https://doi.org/10.1093/infdis/jir658Thwaites G., Nguyen N.V. Linezolid for Drug-Resistant Tuberculosis // The New England journal of medicine. – 2022. – Vol. 387, № 9. – Р. 842-843. https://doi.org/10.1056/NEJMe2208554Thwaites G., Nguyen N.V. Linezolid for drug-resistant tuberculosis. The New England Journal of Medicine, 2022, vol. 387, no. 9, pp. 842-843. https://doi.org/10.1056/NEJMe2208554Tiddens H.A., Bos A.C., Mouton J.W., Devadason S., Janssens H.M. Inhaled antibiotics: dry or wet? // The European respiratory journal. – 2014. – Vol. 44, № 5. – Р. 1308-1318. https://doi.org/10.1183/09031936.00090314Tiddens H.A., Bos A.C., Mouton J.W., Devadason S., Janssens H.M. Inhaled antibiotics: dry or wet? The European Respiratory Journal, 2014, vol. 44, no. 5, pp. 1308-1318. https://doi.org/10.1183/09031936.00090314van Rensburg L., van Zyl J.M., Smith J. Deposition and transport of linezolid mediated by a synthetic surfactant Synsurf® within a pressurized metered dose inhaler: a Calu-3 model // Drug Des Devel Ther. – 2018. – № 12. – Р. 1107-1118. https://doi.org/10.2147/DDDT.S147035van Rensburg L., van Zyl J.M., Smith J. Deposition and transport of linezolid mediated by a synthetic surfactant Synsurf® within a pressurized metered dose inhaler: a Calu-3 model. Drug Des. Devel. Ther., 2018, no. 12, pp. 1107-1118. https://doi.org/10.2147/DDDT.S147035Vasilyeva I.A., Sterlikov S.A., Testov V.V., et al. Sectoral and economic indicators of anti-tuberculosis work in 2022–2023: statistical materials» - M.: FGBU «NMIC FPI» MINZDRAVA ROSSII, 2024. – 59 р.Vasilyeva I.A., Sterlikov S.A., Testov V.V. et al. Sectoral and economic indicators of anti-tuberculosis work in 2022–2023: statistical materials. Moscow, FGBU NMIC FPI MINZDRAVA ROSSII Publ., 2024, 59 p.Verbeeck R.K., Günther G., Kibuule D., Hunter C., Rennie T.W. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring // European journal of clinical pharmacology. – 2016. – Vol. 72, № 8. – Р. 905-916. https://doi.org/10.1007/s00228-016-2083-4Verbeeck R.K., Günther G., Kibuule D., Hunter C., Rennie T.W. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. European Journal of Clinical Pharmacology, 2016, vol. 72, no. 8, pp. 905-916. https://doi.org/10.1007/s00228-016-2083-4Virmani T., Kumar G., Virmani R., Sharma A., Pathak K. Nanocarrier-based approaches to combat chronic obstructive pulmonary disease // Nanomedicine (London, England). – 2022. – Vol. 17, № 24. – Р. 1833-1854. https://doi.org/10.2217/nnm-2021-0403Virmani T., Kumar G., Virmani R., Sharma A., Pathak K. Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. Nanomedicine (London, England), 2022, vol. 17, no. 24, pp. 1833-1854. https://doi.org/10.2217/nnm-2021-0403Virmani, T., Kumar, G., Sharma, A., Pathak, K., Akhtar, M. S., Afzal, O., & Altamimi, A.S.A. Amelioration of Cancer Employing Chitosan, Its Derivatives, and Chitosan-Based Nanoparticles: Recent Updates // Polymers. – 2023. – Vol. 15, № 13. – Р. 2928. https://doi.org/10.3390/polym15132928Virmani T., Kumar G., Sharma A., Pathak K., Akhtar M.S., Afzal O., Altamimi A.S.A. Amelioration of cancer employing chitosan, its derivatives, and chitosan-based nanoparticles: recent updates. Polymers, 2023, vol. 15, no. 13, pp. 2928. https://doi.org/10.3390/polym15132928Warsi M.H., Mohapatra S., Asfer M., Yusuf M., Ali A., Rahman M.A., Ali A., Qadir A., Jain G.K. Development and Antibacterial Investigation of Linezolid-Loaded SPIONs and HPLC Method Development for Quantitative Analysis of Linezolid // J AOAC Int. – 2023. – Vol. 106. № 5. – Р. 1180-1189. https://doi.org/10.1093/jaoacint/qsad071Warsi M.H., Mohapatra S., Asfer M., Yusuf M., Ali A., Rahman M.A., Ali A., Qadir A., Jain G.K. Development and antibacterial investigation of linezolid-loaded spions and hplc method development for quantitative analysis of linezolid. J AOAC Int., 2023, vol. 106, no. 5, pp. 1180-1189. https://doi.org/10.1093/jaoacint/qsad071Wenzler E., Fraidenburg D.R., Scardina T., Danziger L.H. Inhaled Antibiotics for Gram-Negative Respiratory Infections // Clinical microbiology reviews. – 2016 – Vol. 29, № 3. – Р. 581-632. https://doi.org/10.1128/CMR.00101-15Wenzler E., Fraidenburg D.R., Scardina T., Danziger L.H. Inhaled antibiotics for gram-negative respiratory infections. Clinical Microbiology Reviews, 2016, vol. 29, no. 3, pp. 581-632. https://doi.org/10.1128/CMR.00101-15WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva, World Health Organization, 2022, 150 p.WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva, World Health Organization, 2022, 150 p.Zhang P., Li W., Liu M., Zhan S., Zhang H., Deng G., Chen X. Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China // Infect Drug Resist. – 2022. – № 15. – Р. 2617-2624. https://doi.org/10.2147/IDR.S365371Zhang P., Li W., Liu M., Zhan S., Zhang H., Deng G., Chen X. Linezolid-associated neuropathy in patients with MDR/XDR tuberculosis in Shenzhen, China. Infect. Drug Resist., 2022, no. 15, pp. 2617-2624. https://doi.org/10.2147/IDR.S365371Zomorodbakhsh S., Abbasian Y., Naghinejad M., Sheikhpour M. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on Mycobacterium tuberculosis // International journal of nanomedicine. – 2020. – № 15. – Р. 5901-5909. https://doi.org/10.2147/IJN.S251524Zomorodbakhsh S., Abbasian Y., Naghinejad M., Sheikhpour M. The effects study of isoniazid conjugated multi-wall carbon nanotubes nanofluid on Mycobacterium tuberculosis. International Journal of Nanomedicine, 2020, no. 15, pp. 5901-5909. https://doi.org/10.2147/IJN.S251524

The authors declare that there are no conflicts of interest present.